Top 5 Monday Downgrades: NXP Semiconductors Analyst Turns Bearish

Monday brought a fresh batch of analyst rating updates, with five notable downgrades spanning several sectors. These shifts offer a quick look at where some Wall Street firms see near-term risks right now.

Five companies saw their ratings cut or downgraded by big-name firms. Replimune Group even got hit with two separate downgrades in a single session. Below, you’ll find the details for each downgrade and closing prices, so you can see how the market reacted at the week’s start.

Table of Contents

Parsons Corp (PSN) Downgraded by Baird

Baird’s Andrew Wittmann downgraded Parsons Corp (PSN) from Outperform to Neutral in a Monday note. He kept the $60 price target intact.

Parsons closed at $56.01, leaving a modest gap to the target after the downgrade. The company, which focuses on engineering and construction services for defense and infrastructure, now faces more caution from analysts as project timelines and bid cycles remain unpredictable.

What this downgrade signals for investors

Baird’s move reflects a more cautious short-term view on PSN’s growth and margins.

The $60 target hasn’t changed, so upside looks limited unless Parsons lands fresh catalysts.

Investors might want to track contract wins, backlog updates, and any changes in defense or infrastructure spending that could shift Parsons’ revenue mix.

Replimune Group (REPL) Downgraded by HC Wainwright and JPMorgan

REPL got hit with two downgrades on Monday. HC Wainwright’s Robert Burns moved the stock from Buy to Sell, and it ended the day at $4.76.

That same session, JP Morgan’s Anupam Rama cut REPL from Neutral to Underweight, marking a second downgrade for the biotech in one trading day. These moves highlight concerns about REPL’s near-term catalysts, funding situation, and the risks tied to its biotech pipeline.

Investor implications for a high-volatility biotech name

Biotech stocks like REPL can swing hard on clinical updates or trial news, so downgrades often pack a punch in the short run.

Two firms cutting ratings in one session puts a spotlight on liquidity, burn rates, and pipeline progress, not just market sentiment.

The closing price scraping historical lows doesn’t help, raising liquidity risk and the chance for big moves if any new data drops.

Hewlett Packard Enterprise (HPE) Downgraded by Raymond James

Raymond James’ Simon Leopold cut HPE from Strong Buy to Outperform and trimmed the price target from $30 to $29. HPE closed at $24.89, well below the new target.

This reflects a more cautious stance on near-term demand for enterprise IT solutions, with macro headwinds and tough competition in the data-center market weighing on expectations.

What the downgrade implies for IT infrastructure exposure

The downgrade suggests weaker expectations for immediate growth in enterprise spending on servers, storage, and networking gear.

With the target only slightly reduced, upside looks muted unless HPE lands new contracts or launches major new products.

Investors may want to watch IT demand trends, cloud adoption, and whether HPE can tap into hybrid work tailwinds.

NXP Semiconductors (NXPI) Downgraded by BofA Securities

BofA Securities’ Vivek Arya downgraded NXPI from Buy to Neutral and slashed the price target from $245 to $230. NXPI finished at $204.37, well under the new target.

This downgrade points to a more cautious view on near-term semiconductor cycles, especially in mobile and automotive markets, where demand looks shaky.

Implications for the semiconductor sector investors

The downgrade signals hesitation about how quickly demand will bounce back, particularly in consumer electronics and automotive end markets.

The lower target hints at a need for clearer visibility on supply chains, capacity use, and pricing power in a crowded field.

NXPI holders might focus on whether the company’s diverse end markets or capital allocation can offer some protection—or even support a rebound if things turn around.

Takeaway: What Monday’s Downgrades Tell Us

These five top downgrades show how analysts are recalibrating risk across industrials, biotech, and tech hardware—all in just one trading day.

Downgrades might spark some near-term volatility, but investors really need to weigh these rating changes against company fundamentals and cash flow stability.

Long-term strategic positioning matters too. If you’re curious about upgrades or new analyst coverage, check out Benzinga’s analyst ratings page.

This isn’t investment advice—just informational. Prices and ratings come straight from real-time data and the firms’ own market feeds.

Here is the source article for this story: This NXP Semiconductors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Additional Reading: